Cytokinetics (CYTK) Enterprise Value (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Enterprise Value of -$818.6 million for Q1 2026, up 12.79% year-over-year from -$725.7 million in Q1 2025, and up 7.22% quarter-over-quarter from -$882.2 million in Q4 2025.
Cytokinetics (CYTK) Enterprise Value (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Enterprise Value for 17 consecutive years, with -$818.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 12.79% year-over-year to -$818.6 million; the TTM figure through Mar 2026 stood at -$818.6 million (up 12.79% YoY), while the FY2025 annual figure was -$882.2 million, up 18.04% from the prior year.
- Enterprise Value climbed to -$818.6 million in Q1 2026 per CYTK's latest filing, from -$882.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$539.6 million in Q3 2023 and bottomed at -$1.1 billion in Q4 2024.
- Historically, Enterprise Value has averaged -$791.7 million across 5 years, with a median of -$818.6 million in 2026.
- Annual changes were most pronounced in 2023 — Enterprise Value jumped 37.81% — and 2024, when it sank 87.55%.
- Cytokinetics' Enterprise Value stood at -$784.2 million in 2022, then grew by 21.55% to -$615.2 million in 2023, then sank by 74.97% to -$1.1 billion in 2024, then rose by 18.04% to -$882.2 million in 2025, then increased by 7.22% to -$818.6 million in 2026.
- Business Quant data shows CYTK's Enterprise Value at -$818.6 million in Q1 2026, -$882.2 million in Q4 2025, and -$962.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | -1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.17 Bn |
| Mar 31, 2026 | -818.55 Mn |
| Dec 31, 2025 | -882.22 Mn |
| Sep 30, 2025 | -962.54 Mn |
| Jun 30, 2025 | -858.14 Mn |
| Mar 31, 2025 | -938.59 Mn |
| Dec 31, 2024 | -1.08 Bn |
| Sep 30, 2024 | -1.01 Bn |
| Jun 30, 2024 | -1.06 Bn |
| Mar 31, 2024 | -619.34 Mn |
| Dec 31, 2023 | -615.20 Mn |
| Sep 30, 2023 | -539.61 Mn |
| Jun 30, 2023 | -566.10 Mn |
| Mar 31, 2023 | -665.56 Mn |
| Dec 31, 2022 | -784.18 Mn |
| Sep 30, 2022 | -867.66 Mn |
| Jun 30, 2022 | -586.03 Mn |
| Mar 31, 2022 | -608.97 Mn |
| Dec 31, 2021 | -471.64 Mn |
| Sep 30, 2021 | -477.64 Mn |